Quest Diagnostics (DGX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $3.12
- EPS estimate
- $2.82
- EPS surprise
- +10.52%
- Revenue surprise
- +2.36%
- Revenue
- $3.0B
- Revenue estimate
- $3.0B
- Reported
- Jul 23, 2026
Quest Diagnostics reported Q2 2026 results on July 23, 2026. Earnings per share came in at $3.12, ahead of the $2.82 estimate by 10.52%. Revenue was $3.0 billion, in line with the consensus. Compared with Q2 2025, EPS rose about 19% from $2.62 and revenue rose about 7% from $2.8 billion.
The longer record shows a dip followed by steady growth. Annual EPS fell from $9.92 in 2022 to $8.71 in 2023, then rose to $8.92 in 2024 and $9.85 in 2025. The first two quarters of 2026 add up to $5.62, about 16% more than the same period a year earlier. Q2 2026 revenue is the highest in the table, and its EPS is the highest since Q1 2022. The EPS high here is $3.96 in Q3 2021, and the low is $1.98 in Q4 2022. Quest topped the EPS estimate in all of the last 20 quarters. Its largest beat was Q3 2021, at 37.72%, and most others were under 8%.
Quest reported Q3 between October 20 and October 24 in each of the past five years. That points to late October 2026 for the next report. It will show whether the year-over-year growth of recent quarters continues.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 23, 2026 | $2.82 | $3.12 | +10.52% | $3.0B | SEC |
| Q1 2026 | Apr 21, 2026 | $2.37 | $2.50 | +5.67% | $2.9B | SEC |
| Q4 2025 | Feb 10, 2026 | $2.37 | $2.42 | +2.10% | $2.8B | SEC |
| Q3 2025 | Oct 21, 2025 | $2.50 | $2.60 | +3.88% | $2.8B | SEC |
| Q2 2025 | Jul 22, 2025 | $2.57 | $2.62 | +1.93% | $2.8B | SEC |
| Q1 2025 | Apr 22, 2025 | $2.15 | $2.21 | +2.71% | $2.7B | SEC |
| Q4 2024 | Jan 30, 2025 | $2.19 | $2.23 | +2.02% | $2.6B | SEC |
| Q3 2024 | Oct 22, 2024 | $2.26 | $2.30 | +1.60% | $2.5B | SEC |
| Q2 2024 | Jul 23, 2024 | $2.33 | $2.35 | +0.65% | $2.4B | SEC |
| Q1 2024 | Apr 23, 2024 | $1.86 | $2.04 | +9.94% | $2.4B | SEC |
| Q4 2023 | Feb 1, 2024 | $2.11 | $2.15 | +1.72% | $2.3B | SEC |
| Q3 2023 | Oct 24, 2023 | $2.19 | $2.22 | +1.45% | $2.3B | SEC |
| Q2 2023 | Jul 26, 2023 | $2.27 | $2.30 | +1.46% | $2.3B | SEC |
| Q1 2023 | Apr 27, 2023 | $1.97 | $2.04 | +3.31% | $2.3B | SEC |
| Q4 2022 | Feb 2, 2023 | $1.91 | $1.98 | +3.61% | $2.3B | SEC |
| Q3 2022 | Oct 20, 2022 | $2.19 | $2.36 | +7.59% | $2.5B | SEC |
| Q2 2022 | Jul 21, 2022 | $2.29 | $2.36 | +2.99% | $2.5B | SEC |
| Q1 2022 | Apr 21, 2022 | $2.99 | $3.22 | +7.62% | $2.6B | SEC |
| Q4 2021 | Feb 3, 2022 | $3.22 | $3.33 | +3.35% | $2.7B | SEC |
| Q3 2021 | Oct 21, 2021 | $2.88 | $3.96 | +37.72% | $2.8B | SEC |
Quarterly revenue
Frequently asked questions
When did Quest Diagnostics (DGX) last report earnings?
Quest Diagnostics last reported on Jul 23, 2026, covering fiscal Q2 2026.
Did DGX beat earnings estimates?
Yes. Quest Diagnostics reported EPS of $3.12 for Q2 2026 against a $2.82 estimate — a 10.52% beat.
How much revenue did DGX report last quarter?
Quest Diagnostics reported $3.0B in revenue for Q2 2026, against a consensus estimate of $3.0B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.